Health Economics›Renal cell carcinoma›Metastatic disease, first-line

Metastatic disease, first-line

Renal cell carcinoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #06	—	R 307 423	28d	~3.6 mo	~9.4 mo	~4	~R 1 229 690 PFS proxy · indirect	15
Lenvatinib and Pembrolizumab Variant #01	—	R 128 546	21d	~23.9 mo	—	~35	~R 4 499 104 PFS proxy · indirect	3
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~8.5 mo	—	~13	~R 744 203 PFS proxy · indirect	1
Erlotinib and Bevacizumab Variant #01	—	R 52 071	28d	~9.9 mo	—	~11	~R 572 783 PFS proxy · indirect	1
Everolimus and Lenvatinib Variant #01	—	R 48 788	21d	~14.7 mo	—	~22	~R 1 073 328 PFS proxy · indirect	4
Bevacizumab and Interferon alfa-2a Variant #01	—	R 19 082	14d	~9.8 mo	~20.8 mo	~22	~R 419 807 PFS proxy · indirect	4

6 of 6 regimens shown